Purespring Therapeutics has secured approval for its UK clinical trial application (CTA) for a Phase I/II trial of its lead programme, PS-002.

Topline results of a Phase II trial reveal that VX-993 did not meet its primary endpoints, meaning Vertex will discontinue its development.

The US FDA has approved Anbogen Therapeutics’ IND application for the oral HDAC1/2/3 inhibitor ABT-301 in preparation for a Phase I/II trial.

Patients who were dosed with Praxis' vormatrigine over eight weeks experienced a 56.3% median reduction in seizure frequency.

For the first time in decades, the pharmaceutical industry has been directly affected by a geopolitical trade negotiation between the US and the EU.